Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. The t:slim X2 is the #1 rated insulin pump and the #1 rated automated insulin delivery system [dQ&A US Patient Panel Q2 2023 (Apr-Jun 2023)].

For more information, visit tandemdiabetes.com.

SAFETY INFORMATION 
Please note that this account is not intended to be used for product support or medical advice. If you are having a medical emergency, please dial 911. If you are having an issue with one of our products and need immediate assistance, please call our 24 hour customer support team at 877-801-6901 and press 1 twice. 

RX ONLY. BOXED WARNING: Should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. For boxed warning and safety information, see tandemdiabetes.com/safetyinfo.


Tandem Diabetes Care

Jordan Pinsker, MD, Chief Medical Officer for Tandem Diabetes Care, shares the key findings of the Control-IQ Observational (CLIO) study, the largest observational study of Control-IQ advanced hybrid closed-loop technology to date. ​
​
RX ONLY. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 55 lbs. Safety info: https://lnkd.in/d3SmUSb ​

Compatibility update: We are thrilled to announce that the mobile bolus feature on the t:connect mobile app is now available on Google devices of the Pixel 4 family and later, and Samsung 24 devices! (Users received an in-app notification earlier that mobile bolus is compatible with Android OS 14.) Find a full list of mobile app compatibility here: https://bit.ly/3SH0Rpw

At Tandem, we promote diversity and work-life balance through Inclusion Communities (otherwise known as Employee Resource Groups).  As part of the Diversity, Equity, and Inclusion (DEI) initiatives at Tandem, Inclusion Communities provide a welcoming and supportive environment where employees can meet, encourage each other, and grow where they feel the most comfortable. 

Tandem is excited to announce a new Inclusion Community coming soon, Black Employees at Tandem (BET). Meet the three founders of BET and hear what brought them together to help Tandem employees love where they work even more. Read more: https://lnkd.in/exqGskr2

The t:slim X2 insulin pump is the first to connect with Freestyle Libre 2 Plus, Dexcom G6, and Dexcom G7. We’ve been integrating with industry-leading CGMs for more than 10 years. Find out more: https://bit.ly/3SJkZHD

Safety info: https://bit.ly/2OKAQsw

Excitement is building for the Advanced Technologies & Treatments for Diabetes (ATTD) annual meeting in Florence, Italy. Mark your calendars because we're bringing innovation to booth #76, and you won't want to miss it!

🗓️ Save the Dates: 6-9 March 2024
📍 Booth #76
⌚ Exclusive Booth Hours (CEST):
Wed., 6 March: 18:30-20:00 
Thu., 7 March: 09:30-17:00
Fri., 8 March: 10:00-17:30
Sat., 9 March: 10:30-15:30

🎙️ Join us for our captivating oral presentations: https://lnkd.in/ejf4yb4A 
1. “High Satisfaction with Control-IQ 1.5 and Lyumjev Insulin in Children, Adolescents and Adults with Type 1 Diabetes” with Carol Levy, MD, CDCES, Professor of Medicine and Obstetrics, Director Mount Sinai Diabetes Center, Icahn School of Medicine at Mount Sinai. 
2. "Real-world Improvements in Glycemic Control and Patient-Reported Outcomes One Year After Initiation of Tandem Control-IQ in People with Type 1 Diabetes" with Jolien De Meulemeester, University Hospitals Leuven - KU Leuven, Leuven.
3. "What Happens when People Don’t Bolus for a Week with t:slim X2 Insulin Pump with Control-IQ Technology?” with Laurel Messer, PhD, MPH, RN, CDCES.

Register today at https://lnkd.in/d2TvbdMg and stop by booth #76 to uncover the brilliance of the t:slim X2 insulin pump (the #1 rated AID system [dQ&A US Patient Panel Q3 2023 {July-Sept. 2023}]), marvel at the Tandem Mobi (the world's smallest, durable AID system [As of Feb., 2024. Data on file, Tandem Diabetes Care]), and dive into the revolutionary Dexcom G7 CGM integration on a global scale. 

👋 See you soon! 

RX ONLY. Indicated for patients with type 1 diabetes, 6 years and older. WARNING: Control-IQ technology should not be used by people under age 6, or who use less than 10 units of insulin/day, or who weigh less than 25 kg. Safety info: https://lnkd.in/d3SmUSb   

#ATTD2024 #TandemDiabetes

Insulet Corporation is a medical device company that develops, manufactures, and markets insulin infusion systems for people with insulin-dependent diabetes.

Insulet

BD is a global medical technology company that manufactures and sells medical devices, instrument systems, and reagents.

BD (Becton, Dickinson and Company)

GlySens is a medical technology company focused on developing long-term implantable continuous glucose monitoring systems for people with diabetes.

GlySens

There are 19 other competitors in the healthcare sector that compete with Tandem Diabetes Care in the medical device industry.

Additional Competitor

Tandem Diabetes Care is an American medical device manufacturer based in San Diego, California. The company develops medical technologies for the treatment of diabetes and specifically insulin infusion therapy.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

news impact assignment basic	general	Mar 7, 2024 3:03 PM	10874082
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 7, 2024 3:03 PM	f27e0af5
company summary	general
signals	general	Mar 7, 2024 3:03 PM	f1f2498e
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 7, 2024 3:03 PM	d8b450bd
translate crunchbase fundingrounds	general
peers	general	Mar 7, 2024 3:03 PM	543f4ecb
news basic	general	Mar 7, 2024 3:03 PM	8d8ffeba
bundesanzeiger	filings	Mar 7, 2024 3:03 PM	7cff302e
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:TANDEMDIABETES

Tandem Diabetes Care, Inc.

Last Close

30.15

21/11 21:00

Market Cap

2.86B

Beta: -

Volume Today

1.84M

Avg: -